Idiotypic-anti-idiotypic complexes and their in vivo metabolismJOHANSSON, Amanda; ERLANDSSON, Ann; ERIKSSON, David et al.Cancer. 2002, Vol 94, Num 4, pp 1306-1313, issn 0008-543X, SUPConference Paper

Radionuclide-antibody conjugates for single-cell cytotoxicityMATTES, M. Jules.Cancer. 2002, Vol 94, Num 4, pp 1215-1223, issn 0008-543X, SUPConference Paper

Combined modality radioimmunotherapy: Promise and perilBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer. 2002, Vol 94, Num 4, pp 1320-1331, issn 0008-543X, SUPConference Paper

Apoptosis induced by low-dose and low-dose-rate radiationMIRZAIE-JONIANI, Homa; ERIKSSON, David; SHEIKHOLVAEZIN, Ali et al.Cancer. 2002, Vol 94, Num 4, pp 1210-1214, issn 0008-543X, SUPConference Paper

The two types of correction of absorbed dose estimates for internal emittersWILLIAMS, Lawrence E; AN LIU; YAMAUCHI, Dave M et al.Cancer. 2002, Vol 94, Num 4, pp 1231-1234, issn 0008-543X, SUPConference Paper

Single tumor cell uptake and dosimetry of technetium-99m Fab' anti-CD22 in low-grade B-cell lymphomaLINDEN, Ola; HINDORF, Cecilia; TENNVALL, Jan et al.Cancer. 2002, Vol 94, Num 4, pp 1270-1274, issn 0008-543X, SUPConference Paper

Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotinZHONGMIN WANG; GARKAVIJ, Michael; TENNVALL, Jan G et al.Cancer. 2002, Vol 94, Num 4, pp 1287-1292, issn 0008-543X, SUPConference Paper

Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myelomaSUPIOT, Stephane; FAIVRE-CHAUVET, Alain; COUTURIER, Olivier et al.Cancer. 2002, Vol 94, Num 4, pp 1202-1209, issn 0008-543X, SUPConference Paper

Outpatient radioimmunotherapy with Bexxar: Closed, clean air reservoir minimizes personnel radiation exposureHARWOOD, Steven J; GIBBONS, Linda K; GOLDNER, Pamela J et al.Cancer. 2002, Vol 94, Num 4, pp 1358-1362, issn 0008-543X, SUPConference Paper

Comparison of four scatter correction methods for patient whole-body imaging during therapeutic trials with iodine-131DELPON, Grégory; FERRER, Ludovic; LENTA, Corinne et al.Cancer. 2002, Vol 94, Num 4, pp 1224-1230, issn 0008-543X, SUPConference Paper

A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selectionFLYNN, Aiden A; GREEN, Alan J; PEDLEY, R. Barbara et al.Cancer. 2002, Vol 94, Num 4, pp 1249-1257, issn 0008-543X, SUPConference Paper

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphomaWISEMAN, Gregory A; LEIGH, Bryan; ERWIN, William D et al.Cancer. 2002, Vol 94, Num 4, pp 1349-1357, issn 0008-543X, SUPConference Paper

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: Results of a pilot studyBEHR, Thomas M; GRIESINGER, Frank; RIGGERT, Joachim et al.Cancer. 2002, Vol 94, Num 4, pp 1363-1372, issn 0008-543X, SUPConference Paper

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer: Results of a Phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14BEHR, Thomas M; LIERSCH, Torsten; GOLDENBERG, David M et al.Cancer. 2002, Vol 94, Num 4, pp 1373-1381, issn 0008-543X, SUPConference Paper